Cantor Fitzgerald Reiterates Overweight on Eli Lilly (LLY) Despite Medicare Coverage Risks, Still Sees Clear Path for Coverage Contingent on Successful Phase 3
Go back to Cantor Fitzgerald Reiterates Overweight on Eli Lilly (LLY) Despite Medicare Coverage Risks, Still Sees Clear Path for Coverage Contingent on Successful Phase 3| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 209.75 -0.08 (0.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $209.83 | 52 Week High | $333.65 | |||
| Open | $208.36 | 52 Week Low | $223.02 | |||
| Day High | $209.84 | P/E | 26.86 | |||
| Day Low | $207.62 | EPS | $7.81 | |||
| Volume | 63,704 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1190.00 +9.84 (0.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1180.16 | 52 Week High | $88.16 | |||
| Open | $1175.20 | 52 Week Low | $67.88 | |||
| Day High | $1190.65 | P/E | 275.46 | |||
| Day Low | $1163.50 | EPS | $4.32 | |||
| Volume | 310,951 | |||||

